Teacher Retirement System of Texas grew its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 6.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 823,882 shares of the biopharmaceutical company’s stock after acquiring an additional 48,729 shares during the quarter. Teacher Retirement System of Texas owned about 0.05% of Bristol-Myers Squibb worth $50,487,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of BMY. Delphi Private Advisors LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $108,000. Atlantic Trust LLC acquired a new stake in Bristol-Myers Squibb during the 2nd quarter worth approximately $111,000. Massey Quick Simon & CO. LLC increased its position in Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. acquired a new stake in Bristol-Myers Squibb during the 3rd quarter worth approximately $122,000. Finally, Acrospire Investment Management LLC increased its position in Bristol-Myers Squibb by 633.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,200 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 1,900 shares in the last quarter. 71.55% of the stock is owned by institutional investors.
A number of analysts recently issued reports on the stock. Citigroup set a $78.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, February 16th. Jefferies Group set a $72.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, February 26th. TheStreet downgraded shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research report on Thursday, March 8th. DZ Bank downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, February 28th. Finally, Bank of America increased their target price on shares of Bristol-Myers Squibb from $64.00 to $68.00 and gave the stock a “neutral” rating in a research report on Monday, March 5th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $66.30.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter last year, the company earned $0.63 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 3.9% on a year-over-year basis. equities research analysts forecast that Bristol-Myers Squibb Co will post 3.21 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.37%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 271.19%.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 4,000 shares of Bristol-Myers Squibb stock in a transaction dated Friday, December 15th. The stock was bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the purchase, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.23% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Co (BMY) Shares Bought by Teacher Retirement System of Texas” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/03/13/bristol-myers-squibb-co-bmy-shares-bought-by-teacher-retirement-system-of-texas.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.